Harvard Medical School

Genia, Columbia, Harvard awarded DNA sequencing technology grant

Friday, September 13, 2013 01:10 PM

Genia Technologies has announced, as part of a research consortium with Columbia University and Harvard Medical School, it has received a Revolutionary Genome Sequencing Technologies—The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the NIH.  The grant, $5.25 million for three years, will be used in collaboration with investigators at Columbia and Harvard to further develop Genia's nanopore-based DNA sequencing platform that allows for single molecule, electrical, real-time analysis.  

More... »

Medistem collaborates with Boston academic researcher

Wednesday, July 31, 2013 11:45 AM

Medistem, developer of Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product, will collaborate with Reza Abdi, M.D., transplant nephrologist at Brigham and Women's Hospital and assistant professor of medicine, Harvard Medical School. The company will provide Abdi with its ERCs and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for type 1 diabetes. The company has FDA clearance to initiate a dose-escalating phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.

More... »

Boston-based Alzheimer's disease research highlighted at Alzheimer's Association International Conference 2013

Tuesday, July 16, 2013 09:35 AM

Three studies reported at the Alzheimer's Association International Conference 2013 (AAIC) demonstrate the vitality and diversity of Alzheimer's disease research being conducted in Boston, the host city for this year's conference.

More... »

Ipsen, Harvard Medical School to collaborate

Monday, July 15, 2013 10:50 AM

Global pharmaceutical company Ipsen has initiated an R&D collaboration on novel engineered botulinum toxins with Harvard Medical School. Ipsen will fund Harvard research for at least three years to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of neurologic diseases.

More... »

Whole genome sequencing of Alzheimer’s patients to be made available to researchers

Friday, July 12, 2013 01:28 PM

The Alzheimer's Association and the Brin Wojcicki Foundation have announced new data has been generated by the "Big Data" project for Alzheimer's disease. The data will be made freely available to researchers worldwide to advance Alzheimer's science.

More... »

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Galenea receives $3M to develop translational EEG biomarkers for schizophrenia

Friday, September 7, 2012 12:22 PM

Researchers at Galenea, based in Cambridge, Mass., and collaborator Dr. Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School, have been awarded a five-year, $3 million grant from the National Institute of Mental Health (NIMH).

More... »

Thirty teams compete to interpret three families' genomes

Monday, August 20, 2012 12:08 PM

In a contest led by Boston Children's Hospital, 30 teams from around the world are vying to interpret the DNA sequences of three children with rare conditions whose cause remains a mystery—with the goal of establishing "best practices" for interpreting genomic data.

More... »

Oracle Institute and Oracle Labs announce research projects

Friday, February 3, 2012 01:27 PM

Oracle Health Sciences Institute, in partnership with Oracle Labs, has announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School, the Coalition Against Major Diseases (CAMD) at the Critical Path Institute and the Human-Computer Interaction Lab (HCIL) at the University of Maryland.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »